A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

EyePoint Pharmaceuticals, Inc.

Summary

A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

Eligibility

Age range: Up to 3 years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Undergoing uncomplicated cataract surgery with or without a posterior chamber intraocular lens (IOL) implantation. * If a contact lens is used for correction of post-operative aphakia, it must be a silicone elastomer lens or a rigid gas permeable lens (no water content). * Other protocol-specified inclusion criteria may apply. Exclusion Criteria: * Presence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, neurological, psychiatric, respiratory, or other medical condition that could increase the risk to the subject as…

Interventions

Locations (9)

EyePoint Investigational Site
Huntington Beach, California
EyePoint Investigational Site
Palo Alto, California
EyePoint Investigative Site
Boston, Massachusetts
EyePoint Investigational Site
Jackson, Mississippi
EyePoint Investigational Site
Omaha, Nebraska
EyePoint Investigational Site
Buffalo, New York